Velleca Mark A. 4
4 · G1 Therapeutics, Inc. · Filed Aug 10, 2023
Insider Transaction Report
Form 4
Velleca Mark A.
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2023-08-08$0.39/sh+57,286$22,342→ 173,286 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-08-08−57,286→ 0 totalExercise: $0.39Exp: 2024-05-09→ Common Stock (57,286 underlying) - Sale
Common Stock
2023-08-08$2.00/sh−57,286$114,492→ 116,000 total - Exercise/Conversion
Common Stock
2023-08-08$0.30/sh+2,714$814→ 118,714 total - Sale
Common Stock
2023-08-08$2.02/sh−2,714$5,482→ 116,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-08-08−2,714→ 242,286 totalExercise: $0.30Exp: 2025-02-27→ Common Stock (2,714 underlying)
Footnotes (3)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price represents the weighted average price with a low of $1.98 and a high of $2.06. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth.
- [F3]All shares underlying this option have vested.